Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019, provides an overview of the Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline landscape.
H5N1 is a type of influenza virus that causes a highly infectious, severe respiratory disease in birds called avian influenza. This virus can spread to humans. Symptoms include fever and cough, acute respiratory distress, shortness of breath/difficulty breathing, abdominal pain and diarrhea. Predisposing factors include work with poultry, touch an infected bird and eating raw or undercooked poultry meat. Treatment includes antiviral medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Influenza A Virus, H5N1 Subtype Infections - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Influenza A Virus, H5N1 Subtype Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 5, 4, 25 and 7 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 2, 4 and 1 molecule, respectively.
Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Influenza A Virus, H5N1 Subtype Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Influenza A Virus, H5N1 Subtype Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Influenza A Virus, H5N1 Subtype Infections - Overview
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Influenza A Virus, H5N1 Subtype Infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Influenza A Virus, H5N1 Subtype Infections - Companies Involved in Therapeutics Development
Abivax SA
Abzyme Therapeutics LLC
AIM ImmunoTech Inc
Akshaya Bio Inc
Altimmune Inc
Aphios Corp
AusBio Ltd
BiondVax Pharmaceuticals Ltd
CEL-SCI Corp
Chicago Biosolutions Inc
CHO Pharma Inc
Cocrystal Pharma Inc
Curevac AG
Declion Pharmaceuticals Inc
FluGen Inc
Gamaleya Federal Research Center of Epidemiology and Microbiology
Gamma Vaccines Pty Ltd
Global BioLife Inc Ltd
Greffex Inc
i2 Pharmaceuticals Inc
Inovio Pharmaceuticals Inc
Johnson & Johnson
Kineta Inc
Medicago Inc
Medigen Inc
NanoViricides Inc
New Amsterdam Sciences Inc
OPKO Health Inc
PeptiDream Inc
Seqirus Ltd
Shionogi & Co Ltd
TechnoVax Inc
Tria Bioscience Corp
Vacthera BioTech GmbH
Vaxart Inc
Vaxine Pty Ltd
Virion Biotherapeutics
Virvio Inc
Influenza A Virus, H5N1 Subtype Infections - Drug Profiles
(oseltamivir phosphate + pimodivir hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
A-06 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ABX-196 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Alferon LDO - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-0205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APP-309 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
baloxavir marboxil - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CC-42344 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CHOS-05 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CV-7302 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DPC-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GamFluVac - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gamma-Flu - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GREFLU/VIE - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HB-36.6 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
infectious disease vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza (quadrivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A /Vietnam/1203/04 (H5N1)] (monovalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] (split virion) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strain A/H5N1] vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H1N1 + A/H3N2 + A/H5N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H5N1 + A/H1N1] vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
influenza [strains A/H5N1 + A/H5N2 + A/H7N2 + A/H7N3 + A/H9N2] (virus like particle) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KIN-1148 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LB-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
M-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MD-2009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MDG-8972 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit Neuraminidase for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NAS-911 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Nasovax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVINF-2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PD-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptides for Influenza Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pimodivir hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
REDEE FLU - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
rintatolimod - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Influenza Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Influenza A Virus H1N1 and H5N1 Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit PB2 for Influenza A Virus Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides for Influenza, HSV and HIV Infections - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TVX-003 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VGX-3400X - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VH-244 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VTH-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Influenza A Virus, H5N1 Subtype Infections - Dormant Projects
Influenza A Virus, H5N1 Subtype Infections - Discontinued Products
Influenza A Virus, H5N1 Subtype Infections - Product Development Milestones
Featured News & Press Releases
Apr 12, 2019: Vaxart to present at the 29th European Congress of Clinical Microbiology & Infectious Diseases
Apr 11, 2019: Altimmune to present NasoVAX Phase 2 data at the World Vaccine Congress in Washington, D.C.
Mar 06, 2019: FDA accepts Genentech’s supplemental new drug application for XOFLUZA (baloxavir marboxil) for the treatment of influenza in people at high risk of complications
Sep 17, 2018: Virion Appoints Vanessa King as President & CEO and Isabel Najera as CSO
Jul 09, 2018: Hemispherx Files Positive Safety Report on Intranasal Use of Ampligen in Combination with FluMist Influenza Vaccine
Apr 24, 2017: Shionogi Presents New Clinical and Non-clinical Data on S-033188, an Investigational Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Apr 17, 2017: Shionogi to Present New Data on S-033188, a Cap-Dependent Endonuclease Inhibitor for Treatment of Influenza, at the 27th European Congress of Clinical Microbiology and Infectious Diseases
Sep 01, 2016: Abzyme Awarded Highly Competitive National Institutes of Health Phase II SBIR Grant
Mar 22, 2016: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress
Sep 30, 2015: BiondVax Initiates a Phase IIb Clinical Trial in Europe for its Universal Flu Vaccine for Pandemic Outbreak
Mar 23, 2015: Kineta to Present New Vaccine Adjuvant Data at the World Vaccine Congress in Washington D.C.
Oct 29, 2014: BiondVax Receives Approvals for Patent in Europe and Japan for its Universal Flu Vaccine
Feb 17, 2014: BiondVax will Present Clinical Results and the Company's Strategy for Pandemic Preparedness Ahead of Flu Outbreak at the World Health Organization's Key Influenza Meeting
Feb 10, 2014: BiondVax Receives Patent Registration Approval for Multimeric Multiepitope Influenza Vaccines in Hong Kong as well as Allowance of Patent Registration in US for the Company’s Universal Flu Vaccine
Jan 21, 2014: BiondVax’s universal flu vaccine matches all 6 potentially pandemic flu strains in the world today: H5N1, H5N8, H6N1, H7N 7 , H7N 9 and H10N8
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 8: Products under Development by Universities/Institutes, H2 2019
Table 9: Number of Products by Stage and Target, H2 2019
Table 10: Number of Products by Stage and Mechanism of Action, H2 2019
Table 11: Number of Products by Stage and Route of Administration, H2 2019
Table 12: Number of Products by Stage and Molecule Type, H2 2019
Table 13: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abivax SA, H2 2019
Table 14: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Abzyme Therapeutics LLC, H2 2019
Table 15: Influenza A Virus, H5N1 Subtype Infections - Pipeline by AIM ImmunoTech Inc, H2 2019
Table 16: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Akshaya Bio Inc, H2 2019
Table 17: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Altimmune Inc, H2 2019
Table 18: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Aphios Corp, H2 2019
Table 19: Influenza A Virus, H5N1 Subtype Infections - Pipeline by AusBio Ltd, H2 2019
Table 20: Influenza A Virus, H5N1 Subtype Infections - Pipeline by BiondVax Pharmaceuticals Ltd, H2 2019
Table 21: Influenza A Virus, H5N1 Subtype Infections - Pipeline by CEL-SCI Corp, H2 2019
Table 22: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Chicago Biosolutions Inc, H2 2019
Table 23: Influenza A Virus, H5N1 Subtype Infections - Pipeline by CHO Pharma Inc, H2 2019
Table 24: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Cocrystal Pharma Inc, H2 2019
Table 25: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Curevac AG, H2 2019
Table 26: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Declion Pharmaceuticals Inc, H2 2019
Table 27: Influenza A Virus, H5N1 Subtype Infections - Pipeline by FluGen Inc, H2 2019
Table 28: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gamaleya Federal Research Center of Epidemiology and Microbiology, H2 2019
Table 29: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Gamma Vaccines Pty Ltd, H2 2019
Table 30: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Global BioLife Inc Ltd, H2 2019
Table 31: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Greffex Inc, H2 2019
Table 32: Influenza A Virus, H5N1 Subtype Infections - Pipeline by i2 Pharmaceuticals Inc, H2 2019
Table 33: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Inovio Pharmaceuticals Inc, H2 2019
Table 34: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Johnson & Johnson, H2 2019
Table 35: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Kineta Inc, H2 2019
Table 36: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medicago Inc, H2 2019
Table 37: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Medigen Inc, H2 2019
Table 38: Influenza A Virus, H5N1 Subtype Infections - Pipeline by NanoViricides Inc, H2 2019
Table 39: Influenza A Virus, H5N1 Subtype Infections - Pipeline by New Amsterdam Sciences Inc, H2 2019
Table 40: Influenza A Virus, H5N1 Subtype Infections - Pipeline by OPKO Health Inc, H2 2019
Table 41: Influenza A Virus, H5N1 Subtype Infections - Pipeline by PeptiDream Inc, H2 2019
Table 42: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Seqirus Ltd, H2 2019
Table 43: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Shionogi & Co Ltd, H2 2019
Table 44: Influenza A Virus, H5N1 Subtype Infections - Pipeline by TechnoVax Inc, H2 2019
Table 45: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Tria Bioscience Corp, H2 2019
Table 46: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vacthera BioTech GmbH, H2 2019
Table 47: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxart Inc, H2 2019
Table 48: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Vaxine Pty Ltd, H2 2019
Table 49: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Virion Biotherapeutics, H2 2019
Table 50: Influenza A Virus, H5N1 Subtype Infections - Pipeline by Virvio Inc, H2 2019
Table 51: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019
Table 52: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 53: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..2), H2 2019
Table 54: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..3), H2 2019
Table 55: Influenza A Virus, H5N1 Subtype Infections - Dormant Projects, H2 2019 (Contd..4), H2 2019
Table 56: Influenza A Virus, H5N1 Subtype Infections - Discontinued Products, H2 2019
List of Figures
Figure 1: Number of Products under Development for Influenza A Virus, H5N1 Subtype Infections, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
